Antje Wick

TL;DR: In elderly patients with glioblastoma, the addition of temozolomide to short‐course radiotherapy resulted in longer survival than short‐ Course radiotherapy alone.

TL;DR: Nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma, and additional research is needed to find out why.

TL;DR: This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomUSTine in patients with recurrent glioblastoma, although cedIRanib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.

TL;DR: An 11-feature radiomic signature that allows prediction of survival and stratification of patients with newly diagnosed glioblastoma was identified, and improved performance compared with that of established clinical and radiologic risk models was demonstrated.

TL;DR: An invitro model of hypoxic neuroprotection in cerebellar granule neurons is developed and a sequential requirement for VEGF/VEGFR-2 activation and Akt/PKB phosphorylation for neuronal survival mediated by hypoxic preconditioning is indicated and V EGF is proposed as a hypoxia-induced neurotrophic factor.